Ipsen Pharma Aggregated presentation by day and by market Purchases of own shares from July 1st to 5th 2024 Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) IPSEN 549300M6SGDPB4Z94P11 01/07/2024 FR0010259150 4 400 114,6643 XPAR IPSEN 549300M6SGDPB4Z94P11 01/07/2024 FR0010259150 1 600 114,6941 CEUX IPSEN 549300M6SGDPB4Z94P11 02/07/2024 FR0010259150 5 000 113,7584 XPAR IPSEN 549300M6SGDPB4Z94P11 02/07/2024 FR0010259150 2 000 113,7221 CEUX IPSEN 549300M6SGDPB4Z94P11 03/07/2024 FR0010259150 9 372 112,9871 XPAR IPSEN 549300M6SGDPB4Z94P11 03/07/2024 FR0010259150 4 093 112,9235 CEUX IPSEN 549300M6SGDPB4Z94P11 03/07/2024 FR0010259150 300 112,6383 TQEX IPSEN 549300M6SGDPB4Z94P11 03/07/2024 FR0010259150 235 112,5774 AQEU IPSEN 549300M6SGDPB4Z94P11 04/07/2024 FR0010259150 7 091 114,1958 XPAR IPSEN 549300M6SGDPB4Z94P11 04/07/2024 FR0010259150 2 909 114,1684 CEUX IPSEN 549300M6SGDPB4Z94P11 05/07/2024 FR0010259150 7 561 111,8557 XPAR IPSEN 549300M6SGDPB4Z94P11 05/07/2024 FR0010259150 3 353 111,7468 CEUX IPSEN 549300M6SGDPB4Z94P11 05/07/2024 FR0010259150 838 111,8063 TQEX IPSEN 549300M6SGDPB4Z94P11 05/07/2024 FR0010259150 558 111,8204 AQEU TOTAL 49 310 113,2432 Attachment Weekly report on shares repurchases from July 1st to 5th 2024
IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...